Simcha Therapeutics, a New Haven-based biotech focused on fighting cancer, reports it has raised $40 million in a Series B financing round.
Dr. Aaron Ring, an assistant professor of immunobiology at the Yale School of Medicine who founded the company in 2018, said, “The Series B comes at a pivotal time in Simcha’s development as we have transitioned to a clinical-stage company and continue to build our leadership team.”